Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 10 of 10 entries
Sorted by: Best Match Show Resources per page
Dry heat stress stability evaluation of casein peptide mixture.

Food chemistry

D'Hondt M, Demaré W, Van Dorpe S, Wynendaele E, Burvenich C, Peremans K, De Spiegeleer B.
PMID: 25214337
Food Chem. 2011 Sep 01;128(1):114-22. doi: 10.1016/j.foodchem.2011.03.004. Epub 2011 Mar 05.

During food processing, peptide-containing products often experience thermal stress, which can be voluntary heat treatments to prolong expiration date, or unwanted side-effects, e.g. local heating during powder compaction or milling. No information is currently available on the primary structure...

Cite
D'Hondt M, Demaré W, Van Dorpe S, et al. Dry heat stress stability evaluation of casein peptide mixture. Food Chem. 2011;128(1):114-22doi: 10.1016/j.foodchem.2011.03.004.
D'Hondt, M., Demaré, W., Van Dorpe, S., Wynendaele, E., Burvenich, C., Peremans, K., & De Spiegeleer, B. (2011). Dry heat stress stability evaluation of casein peptide mixture. Food chemistry, 128(1), 114-22. https://doi.org/10.1016/j.foodchem.2011.03.004
D'Hondt, Matthias, et al. "Dry heat stress stability evaluation of casein peptide mixture." Food chemistry vol. 128,1 (2011): 114-22. doi: https://doi.org/10.1016/j.foodchem.2011.03.004
D'Hondt M, Demaré W, Van Dorpe S, Wynendaele E, Burvenich C, Peremans K, De Spiegeleer B. Dry heat stress stability evaluation of casein peptide mixture. Food Chem. 2011 Sep 01;128(1):114-22. doi: 10.1016/j.foodchem.2011.03.004. Epub 2011 Mar 05. PMID: 25214337.
Copy Download .nbib Format: NLM
Reversed-phase fused-core HPLC modeling of peptides.

Journal of pharmaceutical analysis

D'Hondt M, Gevaert B, Stalmans S, Van Dorpe S, Wynendaele E, Peremans K, Burvenich C, De Spiegeleer B.
PMID: 29403802
J Pharm Anal. 2013 Apr;3(2):93-101. doi: 10.1016/j.jpha.2012.11.002. Epub 2012 Nov 30.

Different fused-core stationary phase chemistries (C18, Amide, Phenyl-hexyl and Peptide ES-C18) were used for the analysis of 21 structurally representative model peptides. In addition, the effects of the mobile phase composition (ACN or MeOH as organic modifier; formic acid...

Cite
D'Hondt M, Gevaert B, Stalmans S, et al. Reversed-phase fused-core HPLC modeling of peptides. J Pharm Anal. 2012;3(2):93-101doi: 10.1016/j.jpha.2012.11.002.
D'Hondt, M., Gevaert, B., Stalmans, S., Van Dorpe, S., Wynendaele, E., Peremans, K., Burvenich, C., & De Spiegeleer, B. (2013). Reversed-phase fused-core HPLC modeling of peptides. Journal of pharmaceutical analysis, 3(2), 93-101. https://doi.org/10.1016/j.jpha.2012.11.002
D'Hondt, Matthias, et al. "Reversed-phase fused-core HPLC modeling of peptides." Journal of pharmaceutical analysis vol. 3,2 (2013): 93-101. doi: https://doi.org/10.1016/j.jpha.2012.11.002
D'Hondt M, Gevaert B, Stalmans S, Van Dorpe S, Wynendaele E, Peremans K, Burvenich C, De Spiegeleer B. Reversed-phase fused-core HPLC modeling of peptides. J Pharm Anal. 2013 Apr;3(2):93-101. doi: 10.1016/j.jpha.2012.11.002. Epub 2012 Nov 30. PMID: 29403802; PMCID: PMC5760978.
Copy Download .nbib Format: NLM
Using Belgian pharmacy dispensing data to assess antibiotic use for children in ambulatory care.

BMC pediatrics

Dillen H, Burvenich R, De Burghgraeve T, Verbakel JY.
PMID: 34980037
BMC Pediatr. 2022 Jan 03;22(1):12. doi: 10.1186/s12887-021-03047-7.

BACKGROUND: The desired effect of antibiotics is compromised by the rapid escalation of antimicrobial resistance. Children are particularly at high-risk for unnecessary antibiotic prescribing, which is owing to clinicians' diagnostic uncertainty combined with parents' concerns and expectations. Recent Belgian...

Cite
Dillen H, Burvenich R, De Burghgraeve T, et al. Using Belgian pharmacy dispensing data to assess antibiotic use for children in ambulatory care. BMC Pediatr. 2022;22(1):12doi: 10.1186/s12887-021-03047-7.
Dillen, H., Burvenich, R., De Burghgraeve, T., & Verbakel, J. Y. (2022). Using Belgian pharmacy dispensing data to assess antibiotic use for children in ambulatory care. BMC pediatrics, 22(1), 12. https://doi.org/10.1186/s12887-021-03047-7
Dillen, Hannelore, et al. "Using Belgian pharmacy dispensing data to assess antibiotic use for children in ambulatory care." BMC pediatrics vol. 22,1 (2022): 12. doi: https://doi.org/10.1186/s12887-021-03047-7
Dillen H, Burvenich R, De Burghgraeve T, Verbakel JY. Using Belgian pharmacy dispensing data to assess antibiotic use for children in ambulatory care. BMC Pediatr. 2022 Jan 03;22(1):12. doi: 10.1186/s12887-021-03047-7. PMID: 34980037.
Copy Download .nbib Format: NLM
Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin.

Neuro-oncology advances

Gan HK, Parakh S, Lassman AB, Seow A, Lau E, Lee ST, Ameratunga M, Perchyonok Y, Cao D, Burvenich IJG, O'Keefe GJ, Rigopoulos A, Gomez E, Maag D, Scott AM.
PMID: 34549181
Neurooncol Adv. 2021 Aug 03;3(1):vdab102. doi: 10.1093/noajnl/vdab102. eCollection 2021.

BACKGROUND: The adverse impact of increasing brain tumor size on the efficacy of antibody-drug conjugates (ADCs) was investigated preclinically then validated with clinical data.METHODS—PRECLINICAL STUDY: The impact of tumor size on ADC tumor delivery and treatment response was evaluated...

Cite
Gan HK, Parakh S, Lassman AB, et al. Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin. Neurooncol Adv. 2021;3(1):vdab102doi: 10.1093/noajnl/vdab102.
Gan, H. K., Parakh, S., Lassman, A. B., Seow, A., Lau, E., Lee, S. T., Ameratunga, M., Perchyonok, Y., Cao, D., Burvenich, I. J. G., O'Keefe, G. J., Rigopoulos, A., Gomez, E., Maag, D., & Scott, A. M. (2021). Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin. Neuro-oncology advances, 3(1), vdab102. https://doi.org/10.1093/noajnl/vdab102
Gan, Hui K, et al. "Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin." Neuro-oncology advances vol. 3,1 (2021): vdab102. doi: https://doi.org/10.1093/noajnl/vdab102
Gan HK, Parakh S, Lassman AB, Seow A, Lau E, Lee ST, Ameratunga M, Perchyonok Y, Cao D, Burvenich IJG, O'Keefe GJ, Rigopoulos A, Gomez E, Maag D, Scott AM. Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin. Neurooncol Adv. 2021 Aug 03;3(1):vdab102. doi: 10.1093/noajnl/vdab102. eCollection 2021. PMID: 34549181; PMCID: PMC8446913.
Copy Download .nbib Format: NLM
Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma.

Pharmaceuticals (Basel, Switzerland)

Chia PL, Parakh S, Tsao MS, Pham NA, Gan HK, Cao D, Burvenich IJG, Rigopoulos A, Reilly EB, John T, Scott AM.
PMID: 33023139
Pharmaceuticals (Basel). 2020 Oct 02;13(10). doi: 10.3390/ph13100289.

Epidermal growth factor receptor (EGFR) is highly overexpressed in malignant mesothelioma (MM). MAb806 is a novel anti-EGFR antibody that selectively targets a tumor-selective epitope. MAb806-derived antibody drug conjugates (ADCs), ABT-414, ABBV-221 and ABBV-322, may represent a novel therapeutic strategy...

Cite
Chia PL, Parakh S, Tsao MS, et al. Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma. Pharmaceuticals (Basel). 2020;13(10)doi: 10.3390/ph13100289.
Chia, P. L., Parakh, S., Tsao, M. S., Pham, N. A., Gan, H. K., Cao, D., Burvenich, I. J. G., Rigopoulos, A., Reilly, E. B., John, T., & Scott, A. M. (2020). Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma. Pharmaceuticals (Basel, Switzerland), 13(10), . https://doi.org/10.3390/ph13100289
Chia, Puey-Ling, et al. "Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma." Pharmaceuticals (Basel, Switzerland) vol. 13,10 (2020). doi: https://doi.org/10.3390/ph13100289
Chia PL, Parakh S, Tsao MS, Pham NA, Gan HK, Cao D, Burvenich IJG, Rigopoulos A, Reilly EB, John T, Scott AM. Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma. Pharmaceuticals (Basel). 2020 Oct 02;13(10). doi: 10.3390/ph13100289. PMID: 33023139; PMCID: PMC7601847.
Copy Download .nbib Format: NLM
Engineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancers.

EJNMMI research

Burvenich IJ, Lee FT, O'Keefe GJ, Makris D, Cao D, Gong S, Rigopoulos A, Allan LC, Brechbiel MW, Liu Z, Ramsland PA, Scott AM.
PMID: 26983636
EJNMMI Res. 2016 Dec;6(1):26. doi: 10.1186/s13550-016-0180-0. Epub 2016 Mar 17.

BACKGROUND: The aim of the study was to explore Fc mutations of a humanised anti-Lewis-Y antibody (IgG1) hu3S193 as a strategy to improve therapeutic ratios for therapeutic payload delivery.METHODS: Four hu3S193 variants (I253A, H310A, H435A and I253A/H310A) were generated...

Cite
Burvenich IJ, Lee FT, O'Keefe GJ, et al. Engineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancers. EJNMMI Res. 2016;6(1):26doi: 10.1186/s13550-016-0180-0.
Burvenich, I. J., Lee, F. T., O'Keefe, G. J., Makris, D., Cao, D., Gong, S., Rigopoulos, A., Allan, L. C., Brechbiel, M. W., Liu, Z., Ramsland, P. A., & Scott, A. M. (2016). Engineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancers. EJNMMI research, 6(1), 26. https://doi.org/10.1186/s13550-016-0180-0
Burvenich, Ingrid J G, et al. "Engineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancers." EJNMMI research vol. 6,1 (2016): 26. doi: https://doi.org/10.1186/s13550-016-0180-0
Burvenich IJ, Lee FT, O'Keefe GJ, Makris D, Cao D, Gong S, Rigopoulos A, Allan LC, Brechbiel MW, Liu Z, Ramsland PA, Scott AM. Engineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancers. EJNMMI Res. 2016 Dec;6(1):26. doi: 10.1186/s13550-016-0180-0. Epub 2016 Mar 17. PMID: 26983636; PMCID: PMC4796444.
Copy Download .nbib Format: NLM
Risk evaluation of impurities in topical excipients: The acetol case.

Journal of pharmaceutical analysis

Boonen J, Veryser L, Taevernier L, Roche N, Peremans K, Burvenich C, De Spiegeleer B.
PMID: 29403894
J Pharm Anal. 2014 Oct;4(5):303-315. doi: 10.1016/j.jpha.2013.12.006. Epub 2014 Jan 08.

Pharmaceutical excipients for topical use may contain impurities, which are often neglected from a toxicity qualification viewpoint. The possible impurities in the most frequently used topical excipients were evaluated

Cite
Boonen J, Veryser L, Taevernier L, et al. Risk evaluation of impurities in topical excipients: The acetol case. J Pharm Anal. 2014;4(5):303-315doi: 10.1016/j.jpha.2013.12.006.
Boonen, J., Veryser, L., Taevernier, L., Roche, N., Peremans, K., Burvenich, C., & De Spiegeleer, B. (2014). Risk evaluation of impurities in topical excipients: The acetol case. Journal of pharmaceutical analysis, 4(5), 303-315. https://doi.org/10.1016/j.jpha.2013.12.006
Boonen, Jente, et al. "Risk evaluation of impurities in topical excipients: The acetol case." Journal of pharmaceutical analysis vol. 4,5 (2014): 303-315. doi: https://doi.org/10.1016/j.jpha.2013.12.006
Boonen J, Veryser L, Taevernier L, Roche N, Peremans K, Burvenich C, De Spiegeleer B. Risk evaluation of impurities in topical excipients: The acetol case. J Pharm Anal. 2014 Oct;4(5):303-315. doi: 10.1016/j.jpha.2013.12.006. Epub 2014 Jan 08. PMID: 29403894; PMCID: PMC5761210.
Copy Download .nbib Format: NLM
LC-UV/MS quality analytics of paediatric artemether formulations.

Journal of pharmaceutical analysis

Vandercruyssen K, D'Hondt M, Vergote V, Jansen H, Burvenich C, De Spiegeleer B.
PMID: 29403867
J Pharm Anal. 2014 Feb;4(1):37-52. doi: 10.1016/j.jpha.2013.03.006. Epub 2013 Apr 25.

A highly selective and stability-indicating HPLC-method, combined with appropriate sample preparation steps, is developed for β-artemether assay and profiling of related impurities, including possible degradants, in a complex powder for oral suspension. Following HPLC conditions allowed the required selectivity:...

Cite
Vandercruyssen K, D'Hondt M, Vergote V, et al. LC-UV/MS quality analytics of paediatric artemether formulations. J Pharm Anal. 2013;4(1):37-52doi: 10.1016/j.jpha.2013.03.006.
Vandercruyssen, K., D'Hondt, M., Vergote, V., Jansen, H., Burvenich, C., & De Spiegeleer, B. (2014). LC-UV/MS quality analytics of paediatric artemether formulations. Journal of pharmaceutical analysis, 4(1), 37-52. https://doi.org/10.1016/j.jpha.2013.03.006
Vandercruyssen, Kirsten, et al. "LC-UV/MS quality analytics of paediatric artemether formulations." Journal of pharmaceutical analysis vol. 4,1 (2014): 37-52. doi: https://doi.org/10.1016/j.jpha.2013.03.006
Vandercruyssen K, D'Hondt M, Vergote V, Jansen H, Burvenich C, De Spiegeleer B. LC-UV/MS quality analytics of paediatric artemether formulations. J Pharm Anal. 2014 Feb;4(1):37-52. doi: 10.1016/j.jpha.2013.03.006. Epub 2013 Apr 25. PMID: 29403867; PMCID: PMC5761056.
Copy Download .nbib Format: NLM
A critical quality parameter in quantitative fused-core chromatography: The injection volume.

Journal of pharmaceutical analysis

Boonen J, D'hondt M, Veryser L, Peremans K, Burvenich C, Spiegeleer B.
PMID: 29403835
J Pharm Anal. 2013 Oct;3(5):330-334. doi: 10.1016/j.jpha.2013.02.002. Epub 2013 Feb 17.

As part of the method development, the injection volume as a critical quality attribute in fast fused-core chromatography was evaluated. Spilanthol, a pharmaceutically interesting

Cite
Boonen J, D'hondt M, Veryser L, et al. A critical quality parameter in quantitative fused-core chromatography: The injection volume. J Pharm Anal. 2013;3(5):330-334doi: 10.1016/j.jpha.2013.02.002.
Boonen, J., D'hondt, M., Veryser, L., Peremans, K., Burvenich, C., & Spiegeleer, B. (2013). A critical quality parameter in quantitative fused-core chromatography: The injection volume. Journal of pharmaceutical analysis, 3(5), 330-334. https://doi.org/10.1016/j.jpha.2013.02.002
Boonen, Jente, et al. "A critical quality parameter in quantitative fused-core chromatography: The injection volume." Journal of pharmaceutical analysis vol. 3,5 (2013): 330-334. doi: https://doi.org/10.1016/j.jpha.2013.02.002
Boonen J, D'hondt M, Veryser L, Peremans K, Burvenich C, Spiegeleer B. A critical quality parameter in quantitative fused-core chromatography: The injection volume. J Pharm Anal. 2013 Oct;3(5):330-334. doi: 10.1016/j.jpha.2013.02.002. Epub 2013 Feb 17. PMID: 29403835; PMCID: PMC5760949.
Copy Download .nbib Format: NLM
Using Belgian pharmacy dispensing data to assess antibiotic use for children in ambulatory care.

BMC pediatrics

Dillen H, Burvenich R, De Burghgraeve T, Verbakel JY.
PMID: 34980037
BMC Pediatr. 2022 Jan 03;22(1):12. doi: 10.1186/s12887-021-03047-7.

BACKGROUND: The desired effect of antibiotics is compromised by the rapid escalation of antimicrobial resistance. Children are particularly at high-risk for unnecessary antibiotic prescribing, which is owing to clinicians' diagnostic uncertainty combined with parents' concerns and expectations. Recent Belgian...

Cite
Dillen H, Burvenich R, De Burghgraeve T, et al. Using Belgian pharmacy dispensing data to assess antibiotic use for children in ambulatory care. BMC Pediatr. 2022;22(1):12doi: 10.1186/s12887-021-03047-7.
Dillen, H., Burvenich, R., De Burghgraeve, T., & Verbakel, J. Y. (2022). Using Belgian pharmacy dispensing data to assess antibiotic use for children in ambulatory care. BMC pediatrics, 22(1), 12. https://doi.org/10.1186/s12887-021-03047-7
Dillen, Hannelore, et al. "Using Belgian pharmacy dispensing data to assess antibiotic use for children in ambulatory care." BMC pediatrics vol. 22,1 (2022): 12. doi: https://doi.org/10.1186/s12887-021-03047-7
Dillen H, Burvenich R, De Burghgraeve T, Verbakel JY. Using Belgian pharmacy dispensing data to assess antibiotic use for children in ambulatory care. BMC Pediatr. 2022 Jan 03;22(1):12. doi: 10.1186/s12887-021-03047-7. PMID: 34980037; PMCID: PMC8720940.
Copy Download .nbib Format: NLM
Showing 1 to 10 of 10 entries